Endocannabinoid system contributes to liver injury and inflammation by activation of bone marrow-derived monocytes/macrophages in a CB1-dependent manner

Journal of Immunology

Volumn 195, Issue 7, 2015, Pages 3390-3401

  Mai, Ping ^a   Yang, Le ^a   Tian, Lei ^a   Wang, Lin ^a   Jia, Shuangshuang ^a   Zhang, Yuanyuan ^a   Liu, Xin ^a   Yang, Lin ^a   Li, Liying ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL LIPASE; AMIDASE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 3 RECEPTOR; CARBON TETRACHLORIDE; CYTOKINE; ENDOCANNABINOID; FATTY ACID AMIDOHYDROLASE; LIPOPROTEIN LIPASE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPASE D; PROCOLLAGEN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; RHO KINASE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW DERIVED MACROPHAGE; BONE MARROW DERIVED MONOCYTE; BONE MARROW TRANSPLANTATION; CARBON TETRACHLORIDE INDUCED LIVER INJURY; CELL MIGRATION; CONTROLLED STUDY; CYTOMETRY; DENDRITIC CELL; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; HEPATITIS; IMMUNOFLUORESCENCE; IN VIVO STUDY; LIVER INJURY; LYMPHOCYTE MIGRATION; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TRANSGENIC MOUSE; ADULT; AGED; ANIMAL; CELL CULTURE; CELL MOTION; CHEMICALLY INDUCED; CYTOLOGY; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; INJURIES; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOXIC HEPATITIS;

ADULT; AGED; ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CARBON TETRACHLORIDE; CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; DRUG-INDUCED LIVER INJURY; ENDOCANNABINOIDS; FEMALE; HUMANS; INFLAMMATION; LIPOPROTEIN LIPASE; LIVER; LIVER CIRRHOSIS; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; MIDDLE AGED; MONOCYTES; PHOSPHOLIPASE D; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RETROSPECTIVE STUDIES; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84942474080     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1403205     Document Type: Article

References (43)

1. Fonseca, B. M., M. A. Costa, M. Almada, G. Correia-da-Silva, and N. A. Teixeira. 2013. Endogenous cannabinoids revisited: a biochemistry perspective. Prostaglandins Other Lipid Mediat. 102-103: 13-30.
2. Howlett, A. C., C. S. Breivogel, S. R. Childers, S. A. Deadwyler, R. E. Hampson, and L. J. Porrino. 2004. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47(Suppl. 1): 345-358.
3. Di Marzo, V. 2008. Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov. 7: 438-455.
4. Siegmund, S. V., and R. F. Schwabe. 2008. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G357-G362.
5. Di Marzo, V., S. K. Goparaju, L. Wang, J. Liu, S. Bátkai, Z. Járai, F. Fezza, G. I. Miura, R. D. Palmiter, T. Sugiura, and G. Kunos. 2001. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822-825.
6. Cota, D., G. Marsicano, M. Tschöp, Y. Grübler, C. Flachskamm, M. Schubert, D. Auer, A. Yassouridis, C. Thöne-Reineke, S. Ortmann, et al. 2003. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112: 423-431.
7. Osei-Hyiaman, D., M. DePetrillo, P. Pacher, J. Liu, S. Radaeva, S. Bátkai, J. Harvey-White, K. Mackie, L. Offertáler, L. Wang, and G. Kunos. 2005. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115: 1298-1305.
8. Jeong, W. I., D. Osei-Hyiaman, O. Park, J. Liu, S. Bátkai, P. Mukhopadhyay, N. Horiguchi, J. Harvey-White, G. Marsicano, B. Lutz, et al. 2008. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab. 7: 227-235.
9. Gary-Bobo, M., G. Elachouri, J. F. Gallas, P. Janiak, P. Marini, C. Ravinet-Trillou, M. Chabbert, N. Cruccioli, C. Pfersdorff, C. Roque, et al. 2007. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46: 122-129.
10. Teixeira-Clerc, F., B. Julien, P. Grenard, J. Tran Van Nhieu, V. Deveaux, L. Li, V. Serriere-Lanneau, C. Ledent, A. Mallat, and S. Lotersztajn. 2006. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 12: 671-676.
11. Bátkai, S., Z. Járai, J. A. Wagner, S. K. Goparaju, K. Varga, J. Liu, L. Wang, F. Mirshahi, A. D. Khanolkar, A. Makriyannis, et al. 2001. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat. Med. 7: 827-832.
12. Caraceni, P., M. Domenicali, F. Giannone, and M. Bernardi. 2009. The role of the endocannabinoid system in liver diseases. Best Pract. Res. Clin. Endocrinol. Metab. 23: 65-77.
13. Muñoz-Luque, J., J. Ros, G. Fernández-Varo, S. Tugues, M. Morales-Ruiz, C. E. Alvarez, S. L. Friedman, V. Arroyo, and W. Jiménez. 2008. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J. Pharmacol. Exp. Ther. 324: 475-483.
14. Rajesh, M., H. Pan, P. Mukhopadhyay, S. Bátkai, D. Osei-Hyiaman, G. Haskó, L. Liaudet, B. Gao, and P. Pacher. 2007. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J. Leukoc. Biol. 82: 1382-1389.
15. Louvet, A., F. Teixeira-Clerc, M. N. Chobert, V. Deveaux, C. Pavoine, A. Zimmer, F. Pecker, A. Mallat, and S. Lotersztajn. 2011. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 54: 1217-1226.
16. Geissmann, F., M. G. Manz, S. Jung, M. H. Sieweke, M. Merad, and K. Ley. 2010. Development of monocytes, macrophages, and dendritic cells. Science 327: 656-661.
17. Schuppan, D., and N. H. Afdhal. 2008. Liver cirrhosis. Lancet 371: 838-851.
18. Friedman, S. L. 2000. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275: 2247-2250.
19. Pradere, J. P., J. Kluwe, S. De Minicis, J. J. Jiao, G. Y. Gwak, D. H. Dapito, M. K. Jang, N. D. Guenther, I. Mederacke, R. Friedman, et al. 2013. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 58: 1461-1473.
20. Han, Z., T. Zhu, X. Liu, C. Li, S. Yue, X. Liu, L. Yang, L. Yang, and L. Li. 2012. 15-Deoxy-D12,14 -prostaglandin J2 reduces recruitment of bone marrow-derived monocyte/macrophages in chronic liver injury in mice. Hepatology 56: 350-360.
21. Jourdan, T., G. Godlewski, R. Cinar, A. Bertola, G. Szanda, J. Liu, J. Tam, T. Han, B. Mukhopadhyay, M. C. Skarulis, et al. 2013. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat. Med. 19: 1132-1140.
22. Sugamura, K., S. Sugiyama, T. Nozaki, Y. Matsuzawa, Y. Izumiya, K. Miyata, M. Nakayama, K. Kaikita, T. Obata, M. Takeya, and H. Ogawa. 2009. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119: 28-36.
23. Mukhopadhyay, B., R. Cinar, S. Yin, J. Liu, J. Tam, G. Godlewski, J. Harvey-White, I. Mordi, B. F. Cravatt, S. Lotersztajn, et al. 2011. Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver. Proc. Natl. Acad. Sci. USA 108: 6323-6328.
24. Siegmund, S. V., T. Qian, S. de Minicis, J. Harvey-White, G. Kunos, K. Y. Vinod, B. Hungund, and R. F. Schwabe. 2007. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J. 21: 2798-2806.
25. Hall, A. 2012. Rho family GTPases. Biochem. Soc. Trans. 40: 1378-1382.
26. Xu, R., Z. Zhang, and F. S. Wang. 2012. Liver fibrosis: mechanisms of immunemediated liver injury. Cell. Mol. Immunol. 9: 296-301.
27. Kubes, P., and W. Z. Mehal. 2012. Sterile inflammation in the liver. Gastroenterology 143: 1158-1172.
28. Mallat, A., F. Teixeira-Clerc, and S. Lotersztajn. 2013. Cannabinoid signaling and liver therapeutics. J. Hepatol. 59: 891-896.
29. Osei-Hyiaman, D., J. Liu, L. Zhou, G. Godlewski, J. Harvey-White, W. I. Jeong, S. Bátkai, G. Marsicano, B. Lutz, C. Buettner, and G. Kunos. 2008. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J. Clin. Invest. 118: 3160-3169.
30. Moezi, L., S. A. Gaskari, and S. S. Lee. 2008. Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G649-G653.
31. Caraceni, P., A. M. Pertosa, F. Giannone, M. Domenicali, I. Grattagliano, A. Principe, C. Mastroleo, M. G. Perrelli, J. Cutrin, F. Trevisani, et al. 2009. Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. Gut 58: 1135-1143.
32. Tam, J., J. Liu, B. Mukhopadhyay, R. Cinar, G. Godlewski, and G. Kunos. 2011. Endocannabinoids in liver disease. Hepatology 53: 346-355.
33. Mallat, A., and S. Lotersztajn. 2008. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G9-G12.
34. Adhikary, S., V. P. Kocieda, J. H. Yen, R. F. Tuma, and D. Ganea. 2012. Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood 120: 3741-3749.
35. Raborn, E. S., and G. A. Cabral. 2010. Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 333: 319-327.
36. Schulz, C., E. Gomez Perdiguero, L. Chorro, H. Szabo-Rogers, N. Cagnard, K. Kierdorf, M. Prinz, B. Wu, S. E. Jacobsen, J. W. Pollard, et al. 2012. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336: 86-90.
37. Wynn, T. A., A. Chawla, and J. W. Pollard. 2013. Macrophage biology in development, homeostasis and disease. Nature 496: 445-455.
38. Do, Y., R. J. McKallip, M. Nagarkatti, and P. S. Nagarkatti. 2004. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kBdependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J. Immunol. 173: 2373-2382.
39. Börner, C., A. Bedini, V. Höllt, and J. Kraus. 2008. Analysis of promoter regions regulating basal and interleukin-4-inducible expression of the human CB1 receptor gene in T lymphocytes. Mol. Pharmacol. 73: 1013-1019.
40. Le Foll, B., D. A. Gorelick, and S. R. Goldberg. 2009. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl.) 205: 171-174.
41. Bataller, R., and D. A. Brenner. 2005. Liver fibrosis. J. Clin. Invest. 115: 209-218.
42. Duffield, J. S., S. J. Forbes, C. M. Constandinou, S. Clay, M. Partolina, S. Vuthoori, S. Wu, R. Lang, and J. P. Iredale. 2005. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 115: 56-65.
43. Kwon, H. J., Y. S. Won, O. Park, D. Feng, and B. Gao. 2014. Opposing effects of prednisolone treatment on T/NKT cell- and hepatotoxin-mediated hepatitis in mice. Hepatology 59: 1094-1106.